BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Timpe C, Stegemann S, Barrett A, Mujumdar S. Challenges and opportunities to include patient-centric product design in industrial medicines development to improve therapeutic goals. Br J Clin Pharmacol 2020;86:2020-7. [PMID: 32441052 DOI: 10.1111/bcp.14388] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Meng Z. Phase 3. Fundamentals of Drug Development 2022. [DOI: 10.1002/9781119913276.ch9] [Reference Citation Analysis]
2 Drumond N, Stegemann S. An evaluation of film coating materials and their predicted oro-esophageal gliding performance for solid oral dosage forms. Journal of Drug Delivery Science and Technology 2022;77:103804. [DOI: 10.1016/j.jddst.2022.103804] [Reference Citation Analysis]
3 Wargenau M, Reidemeister S, Klingmann I, Klingmann V. A Composite Endpoint for Acceptability Evaluation of Oral Drug Formulations in the Pediatric Population. Ther Innov Regul Sci 2022. [PMID: 35471561 DOI: 10.1007/s43441-022-00406-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Iqbal S, Iqbal K, Trendova K, Nkasu MM, Al Hajjar H, Alghamdi A. An Investigation of the Role of Digitalization on Goods Distribution and Patient-Centric Supply Chain. 2022 Advances in Science and Engineering Technology International Conferences (ASET) 2022. [DOI: 10.1109/aset53988.2022.9735065] [Reference Citation Analysis]
5 van Riet-Nales DA, van den Bemt B, van Bodegom D, Cerreta F, Dooley B, Eggenschwyler D, Hirschlérova B, Jansen PAF, Karapinar-Çarkit F, Moran A, Span J, Stegemann S, Sundberg K. Commentary on the EMA reflection paper on the pharmaceutical development of medicines for use in the older population. Br J Clin Pharmacol 2022. [PMID: 35141926 DOI: 10.1111/bcp.15207] [Reference Citation Analysis]
6 Wargenau M, Reidemeister S, Klingmann I, Klingmann V. A composite endpoint for acceptability evaluation of oral drug formulations in the pediatric population.. [DOI: 10.1101/2021.08.20.21262333] [Reference Citation Analysis]
7 Drumond N, Stegemann S. Better Medicines for Older Patients: Considerations between Patient Characteristics and Solid Oral Dosage Form Designs to Improve Swallowing Experience. Pharmaceutics 2020;13:E32. [PMID: 33379258 DOI: 10.3390/pharmaceutics13010032] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
8 Stegemann S, van Riet-Nales D, de Boer A. Demographics in the 2020s-Longevity as a challenge for pharmaceutical drug development, prescribing, dispensing, patient care and quality of life. Br J Clin Pharmacol 2020;86:1899-903. [PMID: 32939841 DOI: 10.1111/bcp.14511] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Timpe C, Stegemann S, Barrett A, Mujumdar S. Challenges and opportunities to include patient-centric product design in industrial medicines development to improve therapeutic goals. Br J Clin Pharmacol 2020;86:2020-7. [PMID: 32441052 DOI: 10.1111/bcp.14388] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]